Cargando…

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis pools results from 2 phase 3 studies (ClinicalTrials.gov, NCT02118766 [AD-301]; NCT02118792 [AD-302]) to evaluate crisaborole efficacy in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	SILVERBERG, Jonathan I., TALLMAN, Anna M., PORTS, William C., GERBER, Robert A., TAN, Huaming, ZIELINSKI, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2020
Materias:	Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175045/ https://www.ncbi.nlm.nih.gov/pubmed/32318744 http://dx.doi.org/10.2340/00015555-3489

Ejemplares similares

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Crisaborole for atopic dermatitis
Publicado: (2019)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
por: Purohit, Vivek, et al.
Publicado: (2020)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Tolerability of Topical Treatments for Atopic Dermatitis
por: Draelos, Zoe D., et al.
Publicado: (2019)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
por: Schlessinger, Joel, et al.
Publicado: (2020)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’
por: Luger, Thomas, et al.
Publicado: (2021)

Associations between atopic dermatitis and other disorders
por: Silverberg, Jonathan I.
Publicado: (2018)

Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Understanding the Burden of Atopic Dermatitis in Africa and the Middle East
por: Al-Afif, Khalid Abdullah Mohammad, et al.
Publicado: (2019)

Phenotypic differences of atopic dermatitis stratified by age
por: Chatrath, Sheena, et al.
Publicado: (2022)

Food allergy testing in atopic dermatitis
por: Ramírez-Marín, Hassiel A., et al.
Publicado: (2022)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
por: Chovatiya, Raj, et al.
Publicado: (2019)

Dermatology for the internist: optimal diagnosis and management of atopic dermatitis
por: Narla, Shanthi, et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Assessment of a causal relationship between body mass index and atopic dermatitis
por: Budu-Aggrey, Ashley, et al.
Publicado: (2021)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

In Vitro Skin Retention of Crisaborole after Topical Application
por: Fantini, Adriana, et al.
Publicado: (2020)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
por: Tam, Idy, et al.
Publicado: (2021)

The severity of atopic dermatitis evaluated with the SCORAD index and the occurrence of bronchial asthma and rhinitis, and the duration of atopic dermatitis
por: Celakovská, Jarmilă, et al.
Publicado: (2016)

Evaluation of the Impact of Serum Vitamin D Levels on the Scoring Atopic Dermatitis Index in Pediatric Atopic Dermatitis
por: Çiçek, Fatih, et al.
Publicado: (2023)

Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index.
por: Di Lorenzo, Gabriele, et al.
Publicado: (2003)

Body mass index and physical activity in early childhood are associated with atopic sensitization, atopic dermatitis and asthma in later childhood
por: Byberg, Kristine Kjer, et al.
Publicado: (2016)

Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity Index
por: Ragamin, Aviël, et al.
Publicado: (2023)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
por: Li, Lijun
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ff79h8160e936r0rkfsg43r5ef